Navigation Links
Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer

Top 5 Global Biotechnology Company Adopts Pharsight's Groundbreaking

Automation Software

MOUNTAIN VIEW, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software and strategic services for optimizing clinical drug development, today announced that a top five global biotechnology company has purchased WinNonlin AutoPilot. This sale marks Pharsight's third new customer win since the release of WinNonlin Autopilot in June of this year.

WinNonlin AutoPilot is configurable software that customers use to automate common or repetitive tasks during clinical pharmacokinetic (PK) analysis and to create report-ready tables and graphs. Using WinNonlin AutoPilot, companies can vastly increase their productivity while improving the quality and consistency of analyses and reports. WinNonlin AutoPilot operates with Pharsight's enterprise PK data management system, Pharsight Knowledgebase Server(TM) (PKS(TM)), and can also be used independently of PKS.

"This purchase illustrates our clients' growing interest in new, innovative tools that yield more productive, regulatory-compliant PK workflows," said Shawn O'Connor, president, chief executive officer and chairman of Pharsight. "Using AutoPilot the client can configure the PK analyses mandated by the Food and Drug Administration for any new drug submission, including business rules and formats. The potential productivity gains from automating this work are large, with the ability to reduce the labor required to generate these outputs by 80%. We believe clients will continue to invest in our market-leading software products because they offer a tangible return on investment as well as a proven pathway to more efficient drug development."

About WinNonlin AutoPilot

WinNonlin AutoPilot orchestrates PK analyses by selecting input data from a user's local file system or PKS, and then directs WinNonlin(R) to perform analyses and produce report-quality tables, figures, and text output (e.g., in Microsoft (R) Excel, SigmaPlot(R), and Microsoft(R) Word) for regulatory submissions and interim reports. Formatted PK analyses outputs must reflect the requirements and SOPs of each research organization, and WinNonlin AutoPilot provides a user-interface that allows extensive configuration of formatting and business rules to enable clear communication of standards and immediate use across the organization. PK analyses that can be automated include noncompartmental analysis for different study designs and inferential statistics (e.g., bioequivalence testing), as well as comparisons between analytes, dose routes or other conditions.

Used in conjunction with PKS and PKS Reporter(TM), WinNonlin AutoPilot provides standardized, regulatory-compliant, secure and automatic generation of routine analyses and reports. Used independently of PKS and PKS Reporter, WinNonlin AutoPilot can provide significant return on investment through productivity gains and quality improvements in PK analysis and reporting.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products. Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at

Forward Looking Statements

The statements in this press release related to the design and performance of the Pharsight WinNonlin AutoPilot product are forward looking statements. Forward-looking statements are inherently speculative, and actual results may differ materially from Pharsight's expectations due to a variety of factors, including: changes in FDA regulations may affect the demand for WinNonlin AutoPilot; and customers may not perceive the benefits of the product to be the same as Pharsight believes them to be. Other risk factors relating to Pharsight are disclosed in the company's most recent Form 10-Q filed with the Securities and Exchange Commission on November 9, 2007. All forward-looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements.

Registered Trademarks and Trademarks

Pharsight, WinNonlin, WinNonlin AutoPilot, Pharsight Knowledgebase Server, PKS, and PKS Reporter are registered trademarks or trademarks of Pharsight Corporation. All other brand or product names mentioned in this document are trademarks or registered trademarks of their respective companies or organizations.

SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Pharsight Achieves First License Sale for Public-Source Database
2. Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007
3. Pharsight Expands Strategic Consulting Services Team
4. Pharsight Hosts Fourth Annual PKS User Group Meeting
5. Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007
6. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
7. Pharsight Announces 1-For-3 Reverse Stock Split
8. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
9. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
10. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
11. Monsanto Company Signs Share Subscription Agreement With Devgen
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... 24, 2015  Clintrax Global, Inc., a worldwide provider of clinical ... today announced that the company has set a new quarterly earnings ... on quarter growth posted for Q3 of 2014 to Q3 of ... Mexico , with the establishment of an ... --> United Kingdom and Mexico ...
(Date:11/24/2015)... , November 24, 2015 ... recent market research report released by Transparency Market Research, ... expand at a CAGR of 17.5% during the period ... Testing Market - Global Industry Analysis, Size, Volume, Share, ... global non-invasive prenatal testing market to reach a valuation ...
(Date:11/24/2015)... ... 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions for production, ... to serve as Chief Operating Officer. , Having joined InSphero in November ... and was promoted to Head of InSphero Diagnostics in 2014. There she has ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
Breaking Biology News(10 mins):